January 6, 2022 10:58 AM EST
R&D

Sang­amo's sick­le cell al­liance with Sanofi grinds to a halt as phar­ma gi­ant switch­es fo­cus to al­lo

Paul Schloesser

Associate Editor

Af­ter show­cas­ing clin­i­cal da­ta at #ASH21 for a sick­le cell dis­ease can­di­date, Sanofi has de­cid­ed to throw in the tow­el on its 8-year part­ner­ship with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times